Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis C

  Free Subscription


24.06.2019

1 Clin Res Hepatol Gastroenterol
1 Eur J Gastroenterol Hepatol
3 Hepatology
1 J Hepatol
1 J Viral Hepat
1 PLoS Genet


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Clin Res Hepatol Gastroenterol

  1. GOMEZ PA, Zucker KM, Chang J, Rowley MW, et al
    Severe pretreatment hepatic steatosis influences response to direct acting antiviral therapy for chronic hepatitis C in a real world setting.
    Clin Res Hepatol Gastroenterol. 2019 Jun 14. pii: S2210-7401(19)30101.
    PubMed     Text format    


    Eur J Gastroenterol Hepatol

  2. GARIOUD A, Heng R, Amiot X, Remy AJ, et al
    Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients.
    Eur J Gastroenterol Hepatol. 2019 Jun 18. doi: 10.1097/MEG.0000000000001450.
    PubMed     Text format     Abstract available


    Hepatology

  3. ROSENTHAL P, Schwarz KB, Gonzalez-Peralta RP, Lin CH, et al
    Sofosbuvir and Ribavirin Therapy for Children 3 to <12 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30821.
    PubMed     Text format     Abstract available

  4. KANWAL F, Kramer JR, Asch SM, Cao Y, et al
    Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30823.
    PubMed     Text format     Abstract available

  5. SCHWARZ KB, Rosenthal P, Murray KF, Honegger JR, et al
    Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30830.
    PubMed     Text format     Abstract available


    J Hepatol

  6. LLANERAS J, Riveiro-Barciela M, Lens S, Diago M, et al
    Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs.
    J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30345.
    PubMed     Text format     Abstract available


    J Viral Hepat

  7. ASSELAH T, Shafran SD, Bourgeois S, Lai CL, et al
    Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4, and 6 infection.
    J Viral Hepat. 2019 Jun 19. doi: 10.1111/jvh.13159.
    PubMed     Text format     Abstract available


    PLoS Genet

  8. PEREZ S, Kaspi A, Domovitz T, Davidovich A, et al
    Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
    PLoS Genet. 2019;15:e1008181.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: